Association between autoimmune gastritis and gastric polyps: Clinical characteristics and risk factors

Table 1 Baseline data showing the demographic data, clinical, biochemical, and histological characteristics of autoimmune gastritis patients

Characteristics
Patients (N)	530
Age (year), median (IQR)	59 (48-67)
Sex (female), n (%)	362 (68.30)
PCA positivity, n (%)	415 (78.3)
IFA positivity, n (%)	131 (24.7)
HP infection positivity, n (%)	91 (17.2)
Anemia, n (%)	212 (40.0)
Iron deficiency anemia, n (%), mild/moderate/severe	163 (30.8), 135/22/6
Pernicious anemia, n (%), mild/moderate/severe	66 (12.5), 48/11/7
Gastrin-17 (pmol/L), median (IQR)	70.44 (18.30-112.97)
PG-I (μg/L), median (IQR)	30.67 (20.08-48.61)
PG-II (μg/L), median (IQR)	8.07 (6.40-11.00)
PG-I/PG-II, median (IQR)	3.74 (2.05-6.20)
Vitamin B12 (pg/mL), median (IQR)	239.00 (136.20-355.50)
Norm, n (%)	331 (62.5)
Low level, n (%)	199 (37.6)
OLGA, n (%)
0	44 (8.3)
I	120 (22.6)
II	179 (33.8)
III	146 (27.6)
IV	41 (7.7)
OLGIM, n (%)
0	134 (25.3)
I	240 (45.3)
II	98 (18.5)
III	45 (8.5)
IV	13 (2.5)
ECL hyperplasia, n (%)	143 (27.0)
Absent	387 (73.0)
Linear	62 (11.7)
Micronodular	46 (8.7)
Macronodular	18 (3.4)
gNET	17 (3.2)

IQR: Interquartile range; PCA: Parietal cell antibodies; IFAs: Intrinsic factor antibodies; HP: Helicobacter pylori; PG: Pepsinogen; OLGA: Operative Link for Gastritis Assessment; OLGIM: Operative Link on Intestinal Metaplasia Assessment; ECL: Enterochromaffin-like; gNET: Gastric neuroendocrine tumor.